Document:

Exhibit 10.33

 

 

    	 

    	 

    

 

 

    	 

    	 

    

 

 

    	 

    	 

    

 

 

    	 

    	 

    

 

 

    	 

    	 

    

 

 

    	 

    	 

    

 

 

    	 

    	 

    

 

 

    	 

    	 

    

 

 

    	 

    	 

    

 

VITRO ZAMORA JOINT DEVELOPMENT AND SUPPLY AGREEMENT

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed on the date first written above by their duly authorized officers.

 

	Vitro Diagnostics Inc.	 	Jack Zamora
	 	 	 	 	 
	By:	/s/ James Musick	 	By:	/s/ Jack Zamora
	 	 	 	 	 
	Title:	President and CEO	 	Title:	M.D.

 

    	 	10Exhibit
10.34

 

CONVERTIBLE
NOTE PURCHASE AGREEMENT

 

This
Convertible Note Purchase Agreement (“Agreement”) is dated as of May 31, 2022 by and among Vitro Biopharma, Inc.,
a Nevada corporation (the “Company”), and the individuals and entities who become parties to this Agreement by executing
and delivering a Convertible Note Purchase Agreement Signature Page in the form of Exhibit A hereto in accordance with Section
2 hereof (collectively, the “Purchasers”).

 

In
consideration of the mutual promises and covenants contained in this Agreement, the parties hereto agree as follows:

 

1.
Authorization; Sale of Notes

 

1.1.
Authorization. The Company has duly authorized the sale and issuance, pursuant to the terms of this Agreement, of Convertible
Promissory Notes in the form attached hereto as Exhibit B (each a “Note” and, collectively, the “Notes”)
in an aggregate amount of up to

$5,000,000.

 

1.2.
Use of Proceeds. The Company will use the proceeds from the sale of the Notes for working capital and other general corporate
purposes.

 

2.
Closings. Subject to the terms and conditions of this Agreement, each closing (a “Closing” and, collectively,
the “Closings”) of the sale and purchase of Notes under this Agreement shall take place remotely via the exchange
of documents and signatures on or after the date hereof (the date of each such Closing, a “Closing Date”). At each
Closing, the Company shall deliver a Note to each Purchaser participating in such Closing in the original principal amount set forth
next to such Purchaser’s name on such Purchaser’s signature page hereto, and each Purchaser shall pay to the Company via
check or wire transfer the purchase price therefor, which shall be equal to such original principal amount.

 

3.
Certain Terms of the Notes.

 

3.1.
Maturity. Each Note shall be due and payable automatically, in accordance with the terms of Section 3.4(d) below, on the date
that is five (5) years from the date hereof (the “Maturity Date”).

 

3.2.
Interest. The principal balance of the Notes shall bear simple interest at a rate of five percent (5%) per annum.

 

3.3.
Payments. Any payments in cash on the Notes shall be made in proportion to the outstanding principal amount each such Note represents
relative to the aggregate outstanding principal amount of all Notes. The Company shall not prepay any portion of the Notes except upon
the occurrence of an Event of Default (as defined below). Any prepayment of principal shall be accompanied by any interest accrued thereon.

 

    	 

    	 

    

 

3.4.
Conversion.

 

(a)
Upon a Qualified Financing. For the purposes of this Agreement, a “Qualified Financing” shall mean a financing
completed after the date hereof involving the sale of equity securities of the Company (or equity securities and securities exchangeable
for or convertible into equity securities) primarily for capital-raising purposes resulting in gross proceeds to the Company of at least
$5,000,000, not including the outstanding principal amount of the Notes, or any other convertible notes of the Company, and, in each
case, any accrued and unpaid interest thereon. Upon the closing of any such Qualified Financing, all principal and interest on each Note
shall automatically convert into that number and type of securities issued in such Qualified Financing (the “Qualified Financing
Securities”) determined by dividing (i) the outstanding principal amount of such Note plus all accrued and unpaid interest
thereon by (ii) the lower of (x) the Discounted Qualified Financing Price (as defined below), and (y) the Capped Price (as defined below).
Each Purchaser agrees that, in connection with the conversion of the Notes in connection with a Qualified Financing in accordance with
this Section 3.4(a), such Purchaser will execute all necessary documents in connection with such Qualified Financing reasonably requested
of the Purchasers, including executing a definitive purchase agreement, investor rights agreement and such other financing agreements
as shall be agreed upon by the Company and the other investors participating in such Qualified Financing.

 

(b)
Upon a Change of Control. Upon the closing of a Change of Control prior to completion of a Qualified Financing, the amount equal
to the outstanding principal of and interest on such Note shall be converted automatically into that number of shares of common stock
of the Company that equals (i) the principal amount of such Note plus any accrued and unpaid interest outstanding on such Note as of
the Election Date divided by (ii) the Capped Price effective immediately prior to such Change of Control. The Note shall thereafter be
cancelled and be of no further force or effect, whether or not delivered to the Company for cancellation. “Change of Control”
means a change in ownership or control of the Company effected through any of the following transactions: (a) a merger, consolidation,
or other reorganization approved by the Company’s stockholders, unless securities representing more than 50% of the total combined
voting power of the voting securities of the successor entity or its direct or indirect parent entity are immediately thereafter beneficially
owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Company’s outstanding
voting securities immediately prior to such transaction; (b) a stockholder-approved sale, transfer, or other disposition of all or substantially
all of the Company’s assets; or (c) the acquisition, directly or indirectly by any person or related group of persons (other than
the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company), of beneficial
ownership (within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended) of securities possessing more than 50%
of the total combined voting power of the Company’s outstanding securities pursuant to a securities purchase transaction or a tender
or exchange offer made directly to the Company’s stockholders; provided, however, that a merger effected exclusively for the purpose
of changing the domicile of the Company shall not be deemed to be a Change of Control; and provided, further, that the term “Change
of Control” shall not apply to equity financings primarily for capital-raising purposes.

 

(c)
Optional Conversion. Upon a notice duly executed by the holder of a Note and delivered to the Company prior to the Maturity Date
and prior to any automatic conversion of the Notes pursuant to this Section 3.4, (the date of such election, the “Election Date”),
such Purchaser shall be entitled to receive in respect of such Purchaser’s Note, that number of shares of common stock of the Company
that equals (i) the principal amount of such Note plus any accrued and unpaid interest outstanding on such Note as of the Election Date
divided by (ii) the Capped Price.

 

    	2

    	 

    

 

(d)
Maturity. Unless the Notes have been previously converted or otherwise repaid prior to the Maturity Date, on the Maturity Date,
the entire outstanding principal amount of such Notes plus all accrued and unpaid interest thereon of the Notes shall be converted automatically
into that number of shares of common stock of the Company determined by dividing the (a) entire outstanding principal amount of such
Notes plus all accrued and unpaid interest thereon by (b) the Capped Price.

 

(e)
Effect of Conversion, Conversion Procedure, Etc. Upon conversion of any Note pursuant to this Section 3, provided that the securities
issued upon such conversion are duly and validly issued and are nonassessable, the Company will be forever released and discharged from
all of its obligations and liabilities under such Note, including without limitation the obligation to pay the principal amount and accrued
interest. In connection with such conversion, the Company shall have the right to set a reference date for the conversion of accrued
interest under the Note. No fractional securities shall be issuable by the Company upon conversion of any Note. In lieu of any fractional
security which would otherwise be issuable upon conversion of any Note, the Company shall pay to the holder of such Note an amount in
cash equal to the product of such fraction multiplied by the applicable conversion price. The Company shall deliver written notice to
the holder at the holder’s address, notifying the holder of the conversion and specifying the number, class, and series, if applicable,
of securities into which the note is being converted. Upon conversion of each Note, the holder thereof shall surrender such Note, duly
endorsed, at the principal offices of the Company or any transfer agent of the Company. Following such surrender, the Company will, at
its expense, issue and deliver to the such holder, at such principal office, a certificate or certificates for the securities to which
such holder is entitled as a result of such conversion and a check payable to such holder for any cash amounts payable in lieu of any
fractional share or unit in accordance with this Section 3.4.

 

3.5.
Events of Default.

 

(a)
Each of the following shall constitute an “Event of Default,” unless waived by holders of Notes representing a majority
of the principal amount then outstanding on the Notes (the “Note Approval Amount”):

 

	 	(i)	the
    failure by the Company to pay or convert any amount due hereunder within ten (10) days of the due date thereof, and such default
    shall continue unremedied for a period of 30 days following receipt of written notice signed by the holder of such failure to pay
	 	 	 
	 	(ii)	the
    involuntary dissolution and liquidation of the Company; or

 

    	3

    	 

    

 

	 	(iii)	the
    appointment of a receiver of any property, the assignment or trust mortgage for the benefit of creditors, the commencement of any
    kind of insolvency proceedings under any bankruptcy or other law relating to the relief of debtors, or the entry of an order for
    relief with respect to the Company in any proceeding pursuant to the United States Bankruptcy Code, as amended.

 

(b)
Upon the occurrence or existence of any Event of Default described in this Section 3.5, immediately and without notice, the outstanding
principal amount of such Note plus all accrued and unpaid interest thereon shall automatically become immediately due and payable, without
presentment, demand, protest, or any other notice of any kind, all of which are hereby expressly waived, anything contained herein to
the contrary notwithstanding. In addition, the holder of the Note may exercise any other right, power, or remedy otherwise permitted
to it by law, either by suit in equity or by action at law, or both.

 

3.6.
Definitions. For purposes of this Section 3:

 

(a)
“Discounted Qualified Financing Price” shall mean, with respect to any Qualified Financing, the per share price at
which the shares of the Qualified Financing Securities are to be sold generally in such Qualified Financing as determined for accounting
purposes under GAAP (not including any discounts applicable as a result of the Notes or any other convertible notes of the Company outstanding
as of such Qualified Financing) multiplied by 0.75 (subject in all instances to a minimum per share price to the holders of $1.00).

 

(b)
“Capped Price” shall mean, with respect to any Qualified Financing, the per share price implied by a fully-diluted
(on an as-converted to common stock basis), pre-money valuation of $400,000,000 for the Company (which valuation includes any increase
to the option pool made prior to or at the time of such Qualified Financing and all other rights to acquire equity of the Company outstanding
at the time of such Qualified Financing (other than the Notes and any other convertible notes of the Company outstanding as of such Qualified
Financing)), and with respect to a Change of Control, optional conversion by the holder or automatic conversion on the Maturity Date
shall mean the per share price of common stock implied by a fully-diluted (on an as-converted to common stock basis), pre-money valuation
of $400,000,000, which valuation includes all outstanding equity and exercisable rights to acquire equity of the Company outstanding
immediately prior to the Change of Control or optional or automatic conversion (excluding in any event the Notes and any other convertible
notes of the Company outstanding as of such Change of Control or optional or automatic conversion).

 

4.
Representations and Warranties of the Company. The Company hereby represents and warrants to each Purchaser as follows:

 

4.1.
Organization and Authority. The Company is a corporation duly organized, validly existing and in good standing under the laws
of the State of Nevada. The Company has the requisite corporate power to own and operate its properties and assets and to carry on its
business as now conducted and as presently proposed to be conducted.

 

    	4

    	 

    

 

4.2.
Power. The Company will have at each Closing Date all requisite corporate power to execute and deliver this Agreement, to issue
each Note and to carry out and perform its obligations under the terms of this Agreement and under the terms of each Note.

 

4.3.
Due Execution. The execution and delivery of this Agreement and the Notes by the Company and the consummation of the transactions
contemplated hereby have been duly authorized by all requisite action on the part of the Company. This Agreement and the Notes to be
issued at such Closing have been duly executed and delivered by the Company and constitute the valid and binding obligation of the Company,
enforceable against the Company in accordance with their terms, except to the extent that such enforcement may be subject to applicable
bankruptcy, insolvency, reorganization, moratorium, or other laws of general application relating to or affecting enforcement of creditors’
rights and laws concerning equitable remedies.

 

5.
Representations, Warranties and Covenants of each Purchaser. Each Purchaser represents and warrants to and covenants with the
Company as follows:

 

5.1.
Authorization. When executed and delivered by the Purchaser, and assuming execution and delivery by the Company, this Agreement
will constitute a valid and binding obligation of the Purchaser, enforceable in accordance with its terms, except to the extent that
such enforcement may be subject to applicable bankruptcy, insolvency, reorganization, moratorium, or other laws of general application
relating to or affecting enforcement of creditors’ rights and laws concerning equitable remedies.

 

5.2.
Brokers and Finders. The Purchaser has not retained any investment banker, broker, or finder in connection with the transactions
contemplated by this Agreement.

 

5.3.
Investment. The Purchaser is acquiring the Note as well as the Qualified Financing Securities (collectively, the “Securities”)
for investment for the Purchaser’s own account, not as a nominee or agent, and not with a view to the sale or distribution of any
part thereof. The Purchaser has no present intention of selling, granting any participation in, or otherwise distributing any Securities.
By executing this Agreement, the Purchaser further represents that it has no contract, undertaking, agreement, or arrangement with any
person to sell, transfer, or grant participation to such person or to any third person, with respect to any Securities.

 

5.4.
No Public Market. The Purchaser understands and acknowledges that the offering of the Securities pursuant to this Agreement will
not be registered under the Securities Act of 1933, as amended (the “Securities Act”), on the grounds that the offering
and sale of securities contemplated by this Agreement are exempt from registration pursuant one or more exemptions under the Securities
Act, including without limitation the exemption provided by Section 4(a)(2) thereof, and that the Company’s reliance upon such
exemption is predicated upon the Purchaser’s representations as set forth in this Agreement. The Holder acknowledges that the Securities
represent “restricted securities” under applicable federal and state securities laws and must be held indefinitely unless
subsequently registered under the Securities Act or unless an exemption from such registration is available. The Purchaser further understands
that no public market now exists for any of the securities issued by the Company and that the Company has given no assurances that a
public market will ever exist for the Company’s securities.

 

    	5

    	 

    

 

5.5.
Experience; Etc. The Purchaser represents that such Purchaser: (a) has such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of a prospective investment in the Note being purchased by the Purchaser;
(b) believes that he, she or it has received all the information requested from the Company that might be necessary or appropriate for
deciding whether to purchase the Note; (c) has had the opportunity to discuss the Company’s business, management, and financial
affairs with the Company’s management; (d) has the ability to bear the economic risks of this investment; and (e) is able, without
materially impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a complete loss on
this investment.

 

5.6.
Accredited Investor. The Purchaser qualifies as an “accredited investor” within the meaning of Regulation D of the
rules and regulations promulgated under the Securities Act. If other than an individual, the holder has not been organized for the specific
purpose of acquiring the Securities.

 

5.7.
Foreign Investors. If the Purchaser is a Non-U.S. person (as defined under Rule 902(k)(2) of the Securities Act), the Purchaser
hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation
to purchase the Securities, including (i) the legal requirements within its jurisdiction for the purchase of the Securities, (ii) any
foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and
(iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer
of the Securities. The Purchaser’s subscription and payment for and continued beneficial ownership of the Securities or any subsequent
issuance of equity securities pursuant to such ownership will not violate any applicable securities or other laws of the Purchaser’s
jurisdiction.

 

5.8
Disclosure of Information. The holder has had an opportunity to discuss the Company’s business, management, financial affairs,
and the terms and conditions of the offering of the Notes with the Company’s management and has had an opportunity to review the
Company’s facilities and the Company has furnished the holder with all documents and other information required for the Holder
to make an informed decision with respect to the purchase of this Note, provided that the foregoing shall not limit or modify the representations
and warranties of the Company in Section 4 of this Note or the right of the Holder to rely thereon. The Holder confirms that the
Company has not given any guarantee or representation as to the potential success, return, effect, or benefit (either legal, regulatory,
tax, financial, accounting, or otherwise) of an investment in the Securities.

 

5.9
Tax and Legal Advice. The holder is not relying on and has not relied on the Company or any of the Company’s officers, directors,
equity holders, representatives, agents, counsel, or advisers, for any advice, including any financial, tax or legal advice in connection
with the transactions contemplated by this Note and the other Securities. The Holder has had an opportunity to consult with its legal
counsel and tax and other advisers regarding the purchase of the Note and associated Securities. The Holder understands that no federal
or state agency has passed upon the merits or risks of an investment in the Securities or made any finding or determination concerning
the fairness or advisability of this investment. The Holder shall be responsible for any and all taxes, duties, and other similar charges
payable in connection with the issuance of the Securities, and hereby agrees to indemnify the Company and its successors and assigns
with respect to same. The Holder understands and acknowledges that the Company’s counsel has acted solely as legal counsel for
the Company with respect to the preparation of this Note and the transactions contemplated hereby, and has not acted as legal counsel
for the Holder in connection therewith.

 

    	6

    	 

    

 

5.10
Securities Act. The holder understands that the Securities shall bear such restrictive legends as the Company and the Company’s
counsel deem necessary or advisable under applicable law or pursuant to this Agreement, including, without limitation, a legend substantially
in the following form:

 

“THE
SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR REGISTERED
OR QUALIFIED UNDER THE SECURITIES OR “BLUE SKY” LAWS OF ANY JURISDICTION. SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED, PLEDGED
OR HYPOTHECATED UNLESS THE REGISTRATION PROVISIONS OF SAID ACT AND THE REGISTRATION, QUALIFICATION AND FILING REQUIREMENTS OF ALL APPLICABLE
JURISDICTIONS HAVE BEEN COMPLIED WITH OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF LEGAL COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED OR THAT THE PROPOSED TRANSACTION WILL BE EXEMPT FROM REGISTRATION, QUALIFICATION AND FILING IN
ALL SUCH JURISDICTIONS.”

 

5.11
No Transfer. No Purchaser may sell or transfer any Note without the prior written consent of the Company.

 

6.
Miscellaneous.

 

6.1.
Participation Rights. Each holder of a Note shall be entitled, by virtue of the purchase of a Note, to purchase in a Qualified
Financing an amount of Qualified Financing Securities up to 200% of the aggregate principal amount of the Note purchased by the holder.
The Company shall give the holder written notice of its intent to conduct a Qualified Financing and the proposed terms of such Qualified
Financing not less than 10 days prior to the closing thereof. The holder shall provide written notice to the Company of its intent to
participate and the amount of Qualified Financing Securities that it intends to purchase.

 

6.2.
Successors and Assigns. This Agreement shall not be assignable by any party without the written consent of the others; provided,
that a merger to which the Company is a party shall not be considered an assignment requiring consent and provided further that the Company
may assign this Agreement without the consent of the parties hereto to any individual or entity that acquires control of the stock, assets
or business of the Company. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
successors and permitted assigns.

 

6.3.
Survival of Representations and Warranties. All representations and warranties contained herein shall survive the execution and
delivery of this Agreement and the Closings.

 

    	7

    	 

    

 

6.4.
Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability
of any other provision of this Agreement.

 

6.5.
Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Colorado
without reference to the conflicts of law provisions thereof.

 

6.6.
Notices. All notices, requests, consents, and other communications under this Agreement shall be in writing and shall be delivered
by hand, sent overnight courier, facsimile or e-mail, or mailed by first class certified or registered mail, return receipt requested,
postage prepaid:

 

	 	(a)	If
    to the Company:
	 	 	 
	 	 	Vitro
    Biopharma, Inc. 
	 	 	4621
    Technology Drive
	 	 	Golden,
    Colorado 80403
	 	 	with
    a copy to:
	 	 	 
	 	 	Polsinelli
    PC
	 	 	1401
    Lawrence Street, Suite 2300
	 	 	Denver,
    CO 80202 
	 	 	Attn:
    Scott A. Berdan
	 	 	E-mail:
    sberdan@polsinelli.com

 

(b)
If to a Purchaser, at the address set forth below the Purchaser’s name on the signature page hereto, or at such other address as
may have been furnished in writing by such Purchaser to the Company.

 

Notices
provided in accordance with this Section 6.6 shall be deemed delivered (i) upon personal delivery with signature required, (ii) one Business
Day after they have been sent to the recipient by reputable overnight courier service (charges prepaid and signature required), (iii)
upon confirmation of successful transmission of a facsimile message containing such notice if sent before 5 p.m., local time of the recipient,
on any Business Day, and as of 9 a.m. local time of the recipient on the next Business Day if sent thereafter, (iv) if sent via e-mail,
upon receipt if sent before 5 p.m., local time of the recipient, on any Business Day, as of 9 a.m. local time of the recipient on the
next Business Day if sent thereafter or on a day that is not a Business Day, or (v) three Business Days after deposit in the United States
mail. The term “Business Day” as used in this Section 6.6 shall mean any day other than Saturday, Sunday or a day
on which banking institutions are not required to be open in the State of Colorado.

 

6.7.
Complete Agreement. This Agreement (including its Exhibits) and the Notes constitutes the entire agreement and understanding of
the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to such
subject matter.

 

    	8

    	 

    

 

6.8. Amendments
and Waivers. This Agreement may be amended, modified or terminated, and the observance of any term of this Agreement may be
waived, with respect to all parties to this Agreement (either generally or in a particular instance and either retroactively or
prospectively), with the written consent of the Company and holders of the Note Approval Amount; provided that no such
amendment, modification or waiver shall be effective to the extent such amendment, modification or waiver adversely affects the
rights of any holder of a Note in a manner different from those of such consenting holders (other than differences related solely to
the different principal amounts of the Notes) without the consent of each such differently affected holder. No waivers of or
exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed
as, a further or continuing waiver of any such term, condition or provision.

 

6.9.
Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine
or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa.

 

6.10.
Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed
to be an original, and all of which shall constitute one and the same document. This Agreement may be executed via facsimile, .pdf or
other form of electronic signature acceptable to the Company.

 

6.11.
Section Headings and References. The section headings are for the convenience of the parties and in no way alter, modify, amend,
limit or restrict the contractual obligations of the parties. Any reference in this agreement to a particular section or subsection shall
refer to a section or subsection of this Agreement, unless specified otherwise.

 

*
* * *

    	9

    	 

    

 

Executed
as of the date first written above.

 

	 	VITRO BIOPHARMA, INC.
	 	 	 
	 	By:
    	/s/
    Nathan Haas
	 	Name:	Nathan
    Haas
	 	Title:	Chief
    Financial Officer

 

    	 

    	 

    

 

EXHIBIT
A

 

Convertible
Note Purchase Agreement Signature Page

 

By
execution and delivery of this signature page, the undersigned hereby agrees that he, she, or it is a Purchaser, as defined in that certain
Convertible Note Purchase Agreement (the “Purchase Agreement”) by and among Vitro Biopharma, Inc., a Nevada corporation
(the “Company”), and the Purchasers (as defined in the Purchase Agreement), dated as of May 31, 2022, acknowledges
having read the representations in the Purchase Agreement contained in the section entitled “Representations, Warranties, and Covenants
of each Purchaser,” and hereby represents that the statements contained therein are complete and accurate with respect to the undersigned
as a Purchaser. The undersigned further hereby agrees that he, she or it is bound by the terms and conditions of the Purchase Agreement
as a “Purchaser” thereunder and authorizes this signature page to be attached to the Purchase Agreement as a counterpart
signature thereto.

 

Executed,
in counterpart, as of the date set forth below.

 

	 	Bruce
    W. Peterson 
	 	Print
    Name of Purchaser (Individual or Entity)
	 	 
	 	/s/
    Bruce Peterson
	 	Signature
    of Purchaser or Authorized Individual
	 	 
	 	 
	 	Print
    Name of Authorized Individual (If Entity)
	 	 
	 	 
	 	Title
    of Authorized Individual (If Entity)
	 	 
	 	Date: 	May 31, 2022

 

	 	Amount Invested: 	$100,000
	 	 
	 	Contact Person: 	Bruce W. Peterson
	 	 
	 	Address: 	[***]
	 	 	 
	 	
	 	Telephone No.: 	[***]
	 	 
	 	Email
    Address: 	[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]